Tapentadol Depot G.L. Pharma 150 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tapentadol depot g.l. pharma 150 mg depottablett

g.l. pharma gmbh - tapentadoltartrat - depottablett - 150 mg - tapentadoltartrat 251,715 mg aktiv substans

Tapentadol Depot G.L. Pharma 250 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tapentadol depot g.l. pharma 250 mg depottablett

g.l. pharma gmbh - tapentadoltartrat - depottablett - 250 mg - tapentadoltartrat 419,525 mg aktiv substans

Hydroxocobalamin G.L. Pharma 1 mg/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hydroxocobalamin g.l. pharma 1 mg/ml injektionsvätska, lösning

g.l. pharma gmbh - hydroxokobalaminacetat - injektionsvätska, lösning - 1 mg/ml - hydroxokobalaminacetat 1,096 mg aktiv substans

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europeiska unionen - svenska - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Paracetamol Panpharma 10 mg/ml Infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paracetamol panpharma 10 mg/ml infusionsvätska, lösning

panpharma sa - paracetamol - infusionsvätska, lösning - 10 mg/ml - glukosmonohydrat hjälpämne; paracetamol 10 mg aktiv substans - paracetamol

Gentamicin Panpharma 40 mg/ml Injektions-/infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gentamicin panpharma 40 mg/ml injektions-/infusionsvätska, lösning

panpharma sa - gentamicinsulfat - injektions-/infusionsvätska, lösning - 40 mg/ml - gentamicinsulfat 67,8 mg aktiv substans

Midazolam Panpharma 1 mg/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 1 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 1 mg/ml - midazolam 1 mg aktiv substans - midazolam

Midazolam Panpharma 5 mg/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 5 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam

Piperacillin/Tazobactam Midas Pharma 4 g/0,5 g Pulver till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

piperacillin/tazobactam midas pharma 4 g/0,5 g pulver till infusionsvätska, lösning

midas pharma gmbh - piperacillinnatrium; tazobaktamnatrium - pulver till infusionsvätska, lösning - 4 g/0,5 g - tazobaktamnatrium aktiv substans; piperacillinnatrium aktiv substans - piperacillin och enzymhämmare

Olanzapin 1A Pharma 10 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

olanzapin 1a pharma 10 mg filmdragerad tablett

1a pharma gmbh - olanzapin - filmdragerad tablett - 10 mg - olanzapin 10 mg aktiv substans; laktosmonohydrat hjälpämne - olanzapin